Home

Rigel Pharmaceuticals, Inc. - Common Stock (RIGL)

21.65
-0.95 (-4.20%)

Rigel Pharmaceuticals is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of various diseases, particularly those with unmet medical needs

The company specializes in molecular medicine, utilizing advanced technology to create targeted treatments for conditions such as cancer and immune disorders. Through its research initiatives, Rigel aims to deliver effective solutions that improve patient outcomes and enhance the quality of life for individuals facing challenging health issues.

SummaryNewsPress ReleasesChartHistoricalFAQ
Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®
ST. LOUIS, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded arrangement with Rigel Pharmaceuticals, Inc, effective October 14, 2024, to include commercial distribution of TAVALISSE® (fostamatinib). TAVALISSE is an oral medicine that can help patients manage chronic immune thrombocytopenia (ITP) by protecting their platelets from destruction.
By AscellaHealth, LLC · Via GlobeNewswire · October 16, 2024
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS
Lately, several companies have garnered attention for various reasons, and this article aims to delve into five of them, offering insights into their recent developments.
Via AB Newswire · February 28, 2024
Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials
EQNX::TICKER_START (NASDAQTCBP),NASDAQ:CRDFNASDAQCRDF)(NASDAQ:CYADNASDAQCYAD,(NASDAQ:RIGLNASDAQ),(NASDAQ:AZNAZN) EQNX::TICKER_END
Via FinancialNewsMedia · January 19, 2023
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Investor Alert: Investigation over Potential Wrongdoingsbwire.com
San Diego, CA -- (SBWIRE) -- 09/27/2021 -- Certain directors of Rigel Pharmaceuticals, Inc. are under investigation over possible breaches of fiduciary duties.
Via SBWire · September 27, 2021
NASDAQ:RIGL Shareholder Notice: Investigation over Possible Securities Laws Violations by Rigel Pharmaceuticals, Inc.sbwire.com
San Diego, CA -- (SBWIRE) -- 08/30/2021 -- An investigation was announced over potential securities laws violations by Rigel Pharmaceuticals, Inc. in connection with certain financial statements.
Via SBWire · August 30, 2021